Compare Incyte Corporation (INCY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kingsoft Cloud Holdings Limited — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B). The key difference: Incyte Corporation is far larger — about 8.4× Kingsoft Cloud Holdings Limited's market cap, and Incyte Corporation is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Kingsoft Cloud Holdings Limited for 12 Days on average.
| INCY | KC | |
|---|---|---|
Market Cap | $22.85B | $2.71B |
Volume | 1,927,029 | 1,993,765 |
Sector | Health | Technology |
52-Week High | $129.93 | $18.21 |
52-Week Low | $83.80 | $8.58 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $18.35B | $3.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Kingsoft Cloud (KC) trades at $8.74, down 5.31% today, with a bearish technical outlook despite recent earnings beats. The company shows strong revenue growth with Q2 2026 revenue up 30.8% year-over-year and improving gross margins, though it remains unprofitable with a -5.46% net income margin. Analyst sentiment is positive with 70% buy ratings and a consensus price target suggesting 60.25% upside potential.
The stock presents a growth opportunity driven by AI cloud services expansion and strategic partnerships, particularly with Xiaomi, but faces execution risks amid ongoing losses and competitive pressures in China's cloud market. Investors should weigh the strong growth trajectory against persistent profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
